HLA-B |
P01889
|
major histocompatibility complex, class I, B
|
|
3.9E-05 |
0.379 |
0.885 |
HLA-A |
P04439
|
major histocompatibility complex, class I, A
|
|
1.3E-03 |
0.370 |
0.846 |
CDKN2B-AS1 |
|
CDKN2B antisense RNA 1
|
|
|
0.491 |
0.769 |
LINC02571 |
|
long intergenic non-protein coding RNA 2571
|
|
|
0.743 |
0.500 |
MECOM |
Q03112
|
MDS1 and EVI1 complex locus
|
|
1.00 |
0.513 |
0.731 |
ZNRD1ASP |
|
zinc ribbon domain containing 1 antisense, pseudogene
|
|
|
0.691 |
0.538 |
GGNBP1 |
Q5YKI7
|
gametogenetin binding protein 1 (pseudogene)
|
|
0.69 |
0.769 |
0.462 |
RAD51B |
O15315
|
RAD51 paralog B
|
|
2.1E-15 |
0.556 |
0.769 |
MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
PCAT1 |
|
prostate cancer associated transcript 1
|
|
|
0.575 |
0.615 |
RTEL1-TNFRSF6B |
|
RTEL1-TNFRSF6B readthrough (NMD candidate)
|
|
|
0.682 |
0.385 |
PTCSC2 |
|
papillary thyroid carcinoma susceptibility candidate 2
|
|
|
0.751 |
0.231 |
HYKK |
A2RU49
|
hydroxylysine kinase
|
|
7.3E-06 |
0.769 |
0.346 |
CCDC26 |
Q8TAB7
|
CCDC26 long non-coding RNA
|
|
|
0.647 |
0.615 |
DRAIC |
|
downregulated RNA in cancer, inhibitor of cell invasion and migration
|
|
|
0.736 |
0.423 |
CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
APOM |
O95445
|
apolipoprotein M
|
|
9.6E-04 |
0.590 |
0.769 |
FARP2 |
O94887
|
FERM, ARH/RhoGEF and pleckstrin domain protein 2
|
|
4.6E-36 |
0.678 |
0.615 |
SP140 |
Q13342
|
SP140 nuclear body protein
|
|
5.0E-08 |
0.691 |
0.577 |
CASC8 |
|
cancer susceptibility 8
|
|
|
0.670 |
0.462 |
PIGU |
Q9H490
|
phosphatidylinositol glycan anchor biosynthesis class U
|
|
1.9E-05 |
0.670 |
0.462 |
TNRC6B |
Q9UPQ9
|
trinucleotide repeat containing adaptor 6B
|
|
1.00 |
0.751 |
0.462 |
PHLDB1 |
Q86UU1
|
pleckstrin homology like domain family B member 1
|
|
0.11 |
0.722 |
0.423 |
EHBP1 |
Q8NDI1
|
EH domain binding protein 1
|
|
0.31 |
0.839 |
0.231 |
KITLG |
P21583
|
KIT ligand
|
|
0.85 |
0.473 |
0.885 |